Breaking News, Collaborations & Alliances

TheraVida, SK Chemicals in South Korea OAB Pact

SK to develop and commercialize THVD-201 and THVD-202

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TheraVida and SK Chemicals Co. have entered a license agreement for two of TheraVida’s combination drug product candidates, THVD-201 and THVD-202. SK Chemicals has exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). THVD-201 has successfully completed Phase I and Phase II development and THVD-202 is completing preclinical development.   SK Chemicals is responsible for costs ass...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters